Nosqing, founded in 2008, is a wholly-owned subsidiary of Aipeng Medical (stock code: 300753, successfully listed on the Shenzhen GEM on December 13, 2018). For more than ten years, Nosqing has been aiming at "light diagnosis and treatment" and has led the development of the brand with this belief, providing comprehensive light diagnosis and treatment solutions for patients with upper airway diseases.

Relying on Aipeng, the company develops and produces integrated innovative products from nose care to sleep health, from hardware to software, consumables to testing equipment, and continuously launches integrated innovative products to lay out light diagnosis and treatment product solutions in the upper airway field. Currently, the products include Nostin series products, Minesant anti-allergic series products, Nosses sign monitoring series products, sleep monitoring series products, etc. Focusing on serving medical institutions, clinical markets, chain pharmacies, maternal and infant markets, it is committed to serving clinical workers and patients based on academic promotion. The first innovative medical concepts such as "sequential treatment of nasal irrigation" and "prescription seawater for nasal diseases". The company's business model covers multiple online and offline channels. Through the influence of multiple channels, it creates more value for customers and maximizes customer value.

In the future, Noschin will further take root in medical science, advocate the patient-centered "light diagnosis and treatment" concept, and advocate the use of safe, convenient, effective, non-invasive and good-compliant diagnosis and treatment methods to achieve easy diagnosis and treatment and comfortable diagnosis and treatment.